Genetic Mutations
391 articles
Having a genetic mutation can make all the difference in treatment choices, and even longer-term survival. Learn more about the importance of genetic testing and molecular profiling.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Can a Pancreatic Cancer Screening Test Become a Reality?
Dr. Felice Schnoll-Sussman discusses screening options for pancreatic cancer and criteria for people who might want to get screened.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
The Pancreatic Standard of Care is No Longer So Standard
Do you want to understand more about how your doctor chooses your treatments? Learn about the standard of care for pancreatic cancer.
New Study Targets Specific BRAF Mutation
One type of BRAF mutation may provide a target for treatment in pancreatic cancer patients, explains Dr. Michael Pishvaian.
A Registry for Those at Risk for Pancreatic Cancer
Dr. Robert Kurtz founded the Pancreatic Tumor Registry at Memorial Sloan Kettering to learn more about the genetic mutations that cause pancreatic cancer.
Treating Cancer By Mutation, Not by Tumor Location
Dr. Conan Kinsey outlines the latest basket trials, which focus on tumor mutation, not the location of the cancer.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Damage as a Way to Repair Pancreatic Cancer
Dr. Talia Golan takes a closer look at the damage caused by the BRCA1/2 mutations to find a way to treat pancreatic cancer.
Taking a Systems Biology Approach to Find a New Pancreatic Cancer Target
Dr. Andrea Califano is using systems biology and cell regulators to find new targets in the search for ways to stop pancreatic cancer cells.
CRISPR: A New Tool to Help Understand Cancer-Linked Mutations
Lukas Dow, Ph.D., is using CRISPR technology to find better ways to fight cancer by editing the genome.
Putting Familial Risk In Perspective
Dr. Alison Klein works to understand the relationship between familial risk and the chances of developing pancreatic cancer.
Reeducating Myself About Pancreatic Cancer
Martin Hynes knew all about pancreatic cancer–as a research director he worked on the development of Gemzar. He was able to have a Whipple and is doing well.
Searching for Potential Pancreatic Cancer Blood Biomarkers
Researchers are using blood samples to follow people considered at risk for developing pancreatic cancer in a trial looking for early detection biomarkers.
Maintenance Chemotherapy Trial for Pancreatic Cancer Patients with the BRCA Mutation
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.